Clinical trial
Safety And Efficacy Of UK-432,097 In Chronic Obstructive Pulmonary Disease.
NCT00430300 · Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00430300 |
|---|---|
| Title | Safety And Efficacy Of UK-432,097 In Chronic Obstructive Pulmonary Disease. |
| Official title | A Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group Study To Evaluate the Efficacy And Safety of UK-432,097 Dry Powder For Inhalation In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease. |
| Lead sponsor | Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pulmonary Disease, Chronic Obstructive |
| Intervention type | Drug |
| Interventions | UK-432, 097, Placebo |
| Enrollment | 87 |
| Start date | Jan 1, 2007 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Feb 1, 2007 |
| Last update posted | Jul 8, 2013 |
| Countries | Australia, Canada, Netherlands, Poland, United Kingdom |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: